Ocugen stock faces December 22 vote on 250 million shares
Published on 10/17/2026 at 19:49 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSScheduled vote and valuation
- Ocugen's shareholder vote is scheduled for December 22, 2026, on a proposal covering 250,000,000 shares.
- Ocugen had a USD 264.6 million market capitalization on October 16, 2026.
- Ocugen stock stood at USD 0.78 on Nasdaq on October 16, 2026 at 4:00 p.m. ET, down 4.10 percent versus the USD 0.81 prior close.
- Ocugen's price-to-earnings ratio was minus 3.09 on October 16, 2026.
A December 22, 2026 shareholder vote will decide whether Ocugen can add 250,000,000 authorized shares, according to an SEC filing dated October 13, 2026. The same filing states that the meeting was postponed on October 14 and will take place at 8:00 a.m. ET. Ocugen stock was last quoted at USD 0.78 on Nasdaq on October 16, 2026 at 4:00 p.m. ET, down 4.10 percent from USD 0.81.
Share authorization remains the key date
The proposal would increase Ocugen's authorized common stock by 250,000,000 shares. The SEC filing says the new meeting will be held virtually and that October 30, 2026 is the new record date for voting eligibility.
The December date is the next clearly scheduled corporate event for the stock. The filing also says that previously submitted proxies remain valid unless stockholders change them.
Nasdaq price stays near the yearly floor
Ocugen's Nasdaq price was USD 0.78 on October 16, 2026, matching the reported 52-week low. The 52-week range extended to USD 2.73, leaving the stock USD 1.95 below its yearly high. Trading volume reached 5,129,306 shares against an average of 6,185,965 shares.
The company remains a clinical-stage biotechnology business focused on gene therapies for ophthalmic diseases. Its market capitalization stood at USD 264.6 million on October 16, 2026, while its price-to-earnings ratio was minus 3.09.
Valuation and peer comparison
OCGN (Nasdaq, USD): minus 4.10 percent, P/E minus 3.09, market capitalization USD 264.6 million.
Editas Medicine (Nasdaq, USD): minus 3.69 percent, P/E minus 3.14, market capitalization USD 360.9 million.
CRISPR Therapeutics (Nasdaq, USD): minus 4.41 percent, P/E minus 10.35, market capitalization USD 4.8 billion.
What the December date means
The December vote gives Ocugen shareholders a defined corporate calendar point after the earlier meeting was postponed. For investors, the proposal connects the stock's capital structure with the next disclosed shareholder decision, while the Nasdaq quote remains at the lower end of its yearly range.
Ocugen stock stood at USD 0.78 on Nasdaq on October 16, 2026 at 4:00 p.m. ET, down 4.10 percent versus the USD 0.81 prior close.
Market context: Market report S&P 500.
